Anzeige
Mehr »
Sonntag, 10.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2ANGZ | ISIN: FR0013183985 | Ticker-Symbol: G49N
Tradegate
08.08.25 | 14:29
0,146 Euro
+3,11 % +0,004
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GENSIGHT BIOLOGICS SA Chart 1 Jahr
5-Tage-Chart
GENSIGHT BIOLOGICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,1390,14709.08.
0,1400,14308.08.

Aktuelle News zur GENSIGHT BIOLOGICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22.07.GenSight Biologics Announces the Closing of Approximately €500,000 of Additional Financing295Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the "Company") (Euronext: SIGHT...
► Artikel lesen
17.07.GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ Gene Therapy221Better baseline visual acuity and thicker baseline optical coherence tomography (OCT) parameters predict better final visual outcome Patients treated during dynamic phase achieve better...
► Artikel lesen
17.07.GenSight Biologics Raises Approx. EUR 500K2
GENSIGHT BIOLOGICS Aktie jetzt für 0€ handeln
17.07.GenSight Biologics Announces an Additional Financing Amounting to Approximately EUR 500,000 from Existing Shareholder352Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the "Company") (Euronext: SIGHT...
► Artikel lesen
08.07.GenSight Biologics Reports Cash Position as of June 30, 2025326Operations funded until early October 2025 as a result of disciplined spending controls Agreement with the ANSM to consider opening the Named Early Access Program (AAC) for LUMEVOQ in France...
► Artikel lesen
03.07.GenSight Biologics Announces the Closing of the Company's c. €4 Million Private Placement364Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the "Company") (Euronext: SIGHT...
► Artikel lesen
01.07.GenSight Biologics Announces Successful Completion of a Private Placement of Close to EUR 4 Million362Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the "Company") (Euronext: SIGHT...
► Artikel lesen
26.06.GenSight Transfers Upstream Phase of LUMEVOQ Manufacturing Process to Catalent3
26.06.GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent283Upstream phase of LUMEVOQ manufacturing process successfully transferred Milestone follows successful manufacture of drug product batch to be used for named early access program (AAC) and...
► Artikel lesen
12.06.GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ Named Early Access Program (AAC) in France418Agreement to consider opening the French Early Access Program expeditiously after approval of a dose-ranging study Design for dose-ranging study submitted, with clinical trial application...
► Artikel lesen
13.05.GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025374Regulatory News: The Combined General Meeting of shareholders of GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing...
► Artikel lesen
23.04.GenSight Biologics Annual General Meeting on May 13, 2025507Procedures for obtaining preparatory documents for the General Meeting Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused...
► Artikel lesen
08.04.GenSight Biologics S.A.: GenSight Biologics Announces the Filing of its 2024 Universal Registration Document436Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal...
► Artikel lesen
07.04.GenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business Update407Operations funded until early June 2025 as a result of disciplined spending controls Discussions with French agency ANSM regarding the early access program (AAC) for LUMEVOQ progressing ...
► Artikel lesen
19.03.GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates448Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal...
► Artikel lesen
17.03.GenSight Biologics Announces LUMEVOQ Scientific Updates at NANOS 2025318Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative...
► Artikel lesen
07.03.GenSight Biologics Announces Financing Amounting to c. €0.9 Million from Existing Investors480Regulatory News: This press release is not being made in and copies of It may not be distributed or sent, directly or indirectly, into the United States, Canada, South Africa, Japan or Australia GenSight...
► Artikel lesen
28.02.GenSight Biologics S.A. reports FY results1
27.02.GenSight Biologics S.A.: GenSight Biologics Reports Estimated Full-Year 2024 Consolidated Financial Results626Review of LUMEVOQ® dossier to resume compassionate access program in France is ongoing; in parallel, work continues on the new RECOVER Phase III clinical trial and marketing application to the...
► Artikel lesen
12.02.GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ Gene Therapy at the Conclusion of the REFLECT Study358Sustained efficacy 5 years after injection in REFLECT Phase III trial Continued benefit at 5 years in bilaterally treated patients: clinically meaningful improvement of at least 15 letters...
► Artikel lesen
Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1